Project Grant R15HL184252
Award Date 8/15/26
Completion Date 4/30/29
Dollars Obligated $561K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Greenville, NC 27858, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $593,985 on September 15, 2025, under Cardiovascular Diseases Research (CFDA 93.837) to develop artificial intelligence techniques that convert photoplethysmography measurements from off-the-shelf wearable devices into multi-lead electrocardiogram signals for real-time evaluation of acute myocardial infarction outside clinical settings. The project addresses a clinical gap: while electrocardiography is the gold...
- The National Heart, Lung, and Blood Institute awarded Texas A&M Engineering Experiment Station $706,159 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a smart wearable continuous cuffless blood pressure, cardiac, and respiratory monitoring system agnostic to skin tone. The recipient will design and build an innovative wearable device integrating multiple non-invasive physiological sensors on the wrist to provide health-grade continuous...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $177,814 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate smartphone-based digital biomarkers for peripheral artery disease and coronary artery disease using photoplethysmography technology. The project seeks to overcome diagnostic barriers in vascular disease detection by creating a scalable, patient-centered solution deployable through mobile...
- The National Heart, Lung, and Blood Institute awarded $782,341 to the University of Pittsburgh on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate an adaptive, artificial intelligence-guided, closed-loop neuromodulation system for real-time prediction and prevention of ventricular arrhythmias in patients with prior myocardial infarction. The system will coordinate spinal cord stimulation and selective cardiac vagus nerve stimulation to...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- The National Heart, Lung, and Blood Institute awarded Emory University $204,803 on March 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate an electrocardiogram-based deep learning model that predicts coronary artery calcium and adverse cardiovascular outcomes in South Asian populations. The project addresses the underestimation of atherosclerotic cardiovascular disease risk in South Asians through an artificial intelligence approach applied to...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
- The National Heart, Lung, and Blood Institute awarded New York University $872,787 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic discovery and validation research on chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease. The award funds development of proteomic signatures to predict major adverse limb events (MALE) and major adverse cardiovascular events (MACE) in CLTI patients, and to guide...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $234,000 to the University of Colorado-Denver under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective study examining the relationship between directly measured skin pigmentation and pulse oximetry bias. The two-year project (September 1, 2025 – August 31, 2027) addresses a critical gap in medical device validation by objectively measuring skin pigmentation to assess its...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $734,986 on August 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct genetic architecture research on natriuretic peptides and their role in blood pressure regulation. The research leverages whole genome sequencing data from multiethnic cohorts—including the Transomics for Precision Medicine cohorts, UK Biobank, and All of Us Research Program—to identify common,...